Anti-NKG2A Antibodies Block HLA-E Tumor Escape

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current immunotherapeutic approaches for head and neck squamous cell carcinoma (HNSCC) are hindered by immune suppression and the tumor escape mechanism involving HLA-E expression, which inhibits NK and T cell cytotoxicity, limiting the effectiveness of treatments.

Innovation Solution

The use of anti-NKG2A antibodies that neutralize the inhibitory activity of human NKG2A, allowing NK cells to lyse HLA-E-expressing HNSCC cells, either as a single agent or in combination with EGFR inhibitors, to enhance cytotoxicity and overcome immune suppression.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If HLA-E is expressed by tumor cells, then tumor cells can evade immune detection, but NK and T cell cytotoxicity is inhibited

Engineering Contradiction:

Improvetumor escape mechanismVSAvoidimmune suppression

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts the harmful immune suppression caused by HLA-E expression into a beneficial therapeutic opportunity by developing anti-NKG2A antibodies that specifically target and block the inhibitory NKG2A receptor. This blockade transforms the tumor's escape mechanism into a therapeutic vulnerability, enabling NK cells to overcome inhibition and kill HLA-E-positive tumor cells more effectively

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the functional state of the NKG2A receptor from an inhibitory to an activated state by blocking its interaction with HLA-E. This parameter change in receptor signaling transforms NK cell response from suppressed to activated, enabling effective cytotoxicity against tumors that previously evaded immune detection

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If conventional immunotherapeutic approaches are used, then treatment can be administered, but effectiveness is limited by immune suppression

Engineering Contradiction:

Improvetreatment administrationVSAvoidtreatment effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent introduces anti-NKG2A antibodies as an intermediary substance that mediates between the tumor cells expressing HLA-E and the NK cells. This intermediary blocks the inhibitory signal transmission from HLA-E to NKG2A, thereby restoring NK cell cytotoxicity and improving treatment effectiveness without requiring direct modification of tumor cells or complex immune system engineering

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If NKG2A inhibitory activity is not neutralized, then NK cells cannot effectively kill HLA-E-expressing tumor cells, but blocking NKG2A requires specific antibody development

Engineering Contradiction:

Improvetumor cell lysisVSAvoidantibody therapy

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent extracts and isolates the specific inhibitory mechanism (NKG2A-HLA-E interaction) from the complex immune system, allowing targeted intervention. By focusing on this specific receptor-ligand pair, the patent develops specialized anti-NKG2A antibodies that precisely block the inhibitory signal without requiring broad-spectrum immune modulation or complex combination therapies

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS11225519B2Treatment of cancers using anti-NKG2A agents

Publication Date: 2022.01.18 INNATE PHARMA SA

AI summary

The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.